15
Participants
Start Date
September 15, 2017
Primary Completion Date
October 25, 2018
Study Completion Date
October 25, 2018
Alprazolam 2mg (2ALP/PLC)
2mg alprazolam administered at night, placebo administered in the morning.
Alprazolam 1mg (1ALP/PLC)
1mg alprazolam administered at night, placebo administered in the morning.
Alprazolam 0.5mg (0.5ALP/PLC)
0.5mg alprazolam administered at night, placebo administered in the morning.
Zolpidem 10mg (ZOL/PLC)
10mg alprazolam administered at night, placebo administered in the morning.
Placebo (PLC/PLC)
Placebo administered at night, placebo administered in the morning.
Alprazolam 1mg (PLC/ALC)
Placebo administered at night, 1mg alprazolam administered in the morning.
Center on Drug and Alcohol Research, Lexington
Lead Sponsor
National Institute on Drug Abuse (NIDA)
NIH
Marion Coe
OTHER